Taltz Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of psoriasis and psoriatic arthritis, availability of targeted biologic treatments, expansion of specialty rheumatology clinics, growing awareness of autoimmune disorders, reimbursement support for biologic therapies.

The growth in the forecast period can be attributed to increasing demand for personalized autoimmune treatments, rising investments in next-generation biologics, expansion of biologic use in early-stage disease, growing focus on patient-centric drug delivery, increasing innovation in inflammatory pathway targeting. Major trends in the forecast period include increasing use of il-17 inhibitors in autoimmune diseases, rising adoption of biologic therapies for chronic inflammation, expansion of self-injectable treatment options, growing focus on long-term disease control, enhanced patient monitoring and adherence programs.

The rising prevalence of autoimmune diseases is expected to drive the growth of the Taltz market in the coming years. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues, causing inflammation and tissue damage. The increase in these conditions is linked to factors such as genetic predisposition, environmental triggers, lifestyle changes, and improved diagnostic techniques that enhance detection and awareness. Taltz treats autoimmune diseases by targeting and inhibiting specific inflammatory pathways, particularly interleukin-17A, reducing inflammation and alleviating symptoms associated with conditions like psoriasis and psoriatic arthritis. For example, in January 2025, the Mayo Clinic reported that approximately 15 million people are estimated to have one or more of 105 autoimmune diseases. Therefore, the growing prevalence of autoimmune disorders is fueling the growth of the Taltz market.

The rise in healthcare spending is also expected to propel the growth of the Taltz market. Healthcare spending encompasses expenditures on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. Growth in healthcare spending is driven by factors such as an aging population, increasing prevalence of chronic diseases, and higher demand for healthcare services. Increased spending enables broader access to advanced biologic therapies like Taltz, supports improved diagnosis rates, and facilitates patient adherence through insurance coverage and support programs. For instance, in November 2025, the OECD reported that in 2024, member countries allocated an average of approximately 9.3% of their GDP to healthcare. Therefore, the rising healthcare expenditure is driving the growth of the Taltz market.

Major companies in the Taltz market are focusing on obtaining drug approvals to expand treatment options and gain a competitive edge. Drug approval involves regulatory evaluation of a medication’s safety, efficacy, and quality based on clinical trial data. For example, in July 2025, Eli Lilly and Company received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending an update to the marketing authorization of Taltz (ixekizumab). This update would expand Taltz’s indication to include juvenile idiopathic arthritis (JIA), specifically juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), for children aged six years and older. Although the active ingredient remains the same, this expansion addresses an unmet pediatric rheumatology need in patients with inadequate response or intolerance to conventional therapy, complementing Taltz’s existing adult indications.

Major companies operating in the taltz market are Eli Lilly and Company.

North America was the largest region in the taltz market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the taltz market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the taltz market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the taltz market by increasing costs of imported biologic ingredients, prefilled syringe components, autoinjector devices, and cold-chain transportation services. Healthcare systems in North America and Europe are most affected due to reliance on cross-border biologics manufacturing and distribution networks, while Asia-Pacific faces higher logistics costs. These tariffs are increasing overall treatment costs and supply chain complexity. However, they are also driving regional manufacturing investments, localized packaging operations, and improved domestic supply chain resilience for biologic autoimmune therapies.

The taltz market research report is one of a series of new reports that provides taltz market statistics, including taltz industry global market size, regional shares, competitors with a taltz market share, detailed taltz market segments, market trends and opportunities, and any further data you may need to thrive in the taltz industry. This taltz market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Taltz (ixekizumab) is a prescription biologic medication used to treat autoimmune conditions, including moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammatory responses, helping to reduce symptoms such as joint pain, skin lesions, and stiffness.

The primary indications for Taltz include psoriasis, psoriatic arthritis, and ankylosing spondylitis. Psoriasis is a chronic skin condition in which the immune system causes skin cells to grow too rapidly, resulting in red, flaky, and inflamed patches, commonly on the elbows, knees, and scalp. Taltz can be administered via subcutaneous injection or intravenous infusion and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is used by both pediatric and adult patients.

The taltz market consists of sales of injectables and immunomodulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.